Home to Silicon Wadi and a long-running streak of mega-money exits, the Tel Aviv tech scene leads with innovative applications of robotics, AI and medtech.
Biotech startup Immunai has been on a roll when it comes to funding. The company that set out to create an atlas of the human immune system in 2018 had raised about $80 million by February 2021. On Wednesday, the company announced another significantly larger round: a $215 million series B. Immunai has been building […]
Creating a map for the immune system israel21c.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from israel21c.org Daily Mail and Mail on Sunday newspapers.
April 1, 2021
By Bio-IT World Staff
April 1, 2021 | New investment funds for late-stage companies and public health. Next-gen genomic medicines and single-cell multiomics get cash, and PatientsLikeMe raises a new round of funding to expand.
$969M Investment Fund for Early to Late-Stage Companies
Foresite Capital, a multi-stage healthcare and life sciences investment firm, has announced its fifth and largest fundraise with $969 million in capital commitments, significantly oversubscribed above its original target. The offering comprises Foresite Capital Fund V, L.P. and Foresite Capital Opportunity Fund V, L.P. With these new funds, Foresite Capital is investing in emerging healthcare and life sciences companies at all stages that are solving some of the biggest inefficiencies and pain points of the $10 trillion global healthcare market. Foresite Capital now has ~$4 billion in assets under management. Press release.